Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
14.66
+0.67 (4.79%)
At close: Jul 29, 2025, 4:00 PM
14.82
+0.16 (1.09%)
After-hours: Jul 29, 2025, 6:09 PM EDT

Company Description

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.

The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.

It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.

The company was incorporated in 2015 and is based in Irvine, California.

Beta Bionics, Inc.
Beta Bionics logo
CountryUnited States
Founded2015
IPO DateJan 30, 2025
IndustryMedical Devices
SectorHealthcare
Employees294
CEOSean Saint

Contact Details

Address:
11 Hughes
Irvine, California 92618
United States
Phone949 427 7785
Websitebetabionics.com

Stock Details

Ticker SymbolBBNX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001674632
CUSIP Number08659B102
ISIN NumberUS08659B1026
Employer ID47-5386878
SIC Code3841

Key Executives

NamePosition
Sean T. Saint PEPresident, Chief Executive Officer and Director
Stephen H. FeiderChief Financial Officer, Treasurer and Secretary
Mark Hopman M.B.A., R.Ph.Chief Commercial Officer
David HendersonVice President of Operations
Blake BeberHead of Investor Relations
Kevin MeinertVice President of Legal and Business Development
Karen Hynes M.B.A.Vice President of Marketing Execution
Dr. Steven Russell M.D., Ph.D.Chief Medical Officer
Mike MensingerChief Product Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 20258-KCurrent Report
Jul 29, 202510-QQuarterly Report
Jun 23, 20258-KCurrent Report
Jun 9, 2025144Filing
May 15, 2025SCHEDULE 13GFiling
May 15, 2025SCHEDULE 13GFiling
May 12, 2025SCHEDULE 13G/AFiling
May 12, 2025SCHEDULE 13GFiling
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report